A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents

Trial Profile

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2018

At a glance

  • Drugs Guadecitabine (Primary) ; Cytarabine; Daunorubicin; Idarubicin; Mitoxantrone
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTRAL-3
  • Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 21 Aug 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top